References
- Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64:1378–1382.
- Chamberlain JM, Klein BL. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med. 1994;12:650–660.
- World Health Organization. WHO Model List of Essential Medicines, 18th Edition. Geneva, Switzerland: World Health Organization; April 2013.
- Wermeling DP. Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access. Ther Adv Drug Saf. 2015;6:20–31.
- Beletsky L. The benefits and potential drawbacks in the approval of EVZIO for lay reversal of opioid overdose. Am J Prev Med. 2015;48:357–359.
- Food and Drug Administration. FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose [press release]. November 18, 2015. Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473505.htm [Accessed July 5, 2016]
- Wheeler E, Jones TS, Gilbert MK, Davidson PJ, Centers for Disease Control and Prevention. Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64:631–635.
- Jones CM, Lurie PG, Compton WM. Increase in naloxone prescriptions dispensed in US retail pharmacies since 2013. Am J Public Health. 2016;106:689–690.
- Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain–United States, 2016. JAMA. 2016;315:1624–1645.
- Lim JK, Bratberg JP, Davis CS, Green TC, Walley AY. Prescribe to prevent: overdose prevention and naloxone rescue kits for prescribers and pharmacists. J Addict Med. 2016;10(5):300–308.
- Beletsky L, Ruthazer R, Macalino GE, Rich JD, Tan L, Burris S. Physicians' knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities. J Urban Health. 2007;84:126–136.
- Binswanger IA, Koester S, Mueller SR, Gardner EM, Goddard K, Glanz JM. Overdose education and naloxone for patients prescribed opioids in primary care: a qualitative study of primary care staff. J Gen Intern Med. 2015;30:1837–1844.
- Katz DA, Williams GC, Brown RL, et al. Emergency physicians' fear of malpractice in evaluating patients with possible acute cardiac ischemia. Ann Emerg Med. 2005;46:525–533.
- Elmore JG, Taplin SH, Barlow WE, et al. Does litigation influence medical practice? The influence of community radiologists' medical malpractice perceptions and experience on screening mammography. Radiology. 2005;236:37–46.
- Lawthers AG, Laird NM, Lipsitz S, Hebert L, Brennan TA, Localio AR. Physicians' perceptions of the risk of being sued. J Health Politics Policy Law. 1992;17:463–482.
- Burris S, Beletsky L, Castagna C, Coyle C, Crowe C, McLaughlin J. Stopping an invisible epidemic: legal issues in the provision of naloxone to prevent opioid overdose. Drexel Law Rev. 2009;1:273–340.
- Burris S, Norland J, Edlin BR. Legal aspects of providing naloxone to heroin users in the United States. Int J drug policy. 2001;12(3):237–248.
- Davis CS, Carr D, Southwell JK, Beletsky L. Engaging law enforcement in overdose reversal initiatives: authorization and liability for naloxone administration. Am J Public Health. 2015;105(8):1530–1537.
- Davis CS, Carr D. Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend. 2015;157:112–120.
- Prescription Drug Abuse Policy System. Naloxone Overdose Prevention Laws. http://www.pdaps.org/dataset/overview/laws-regulating-administration-of-naloxone/. Published 2016. Accessed August 15, 2016.
- Davis CS, Webb D, Burris S. Changing law from barrier to facilitator of opioid overdose prevention. J Law Med Ethics. 2013;41(Suppl 1):33–36.
- Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105–S120.
- Food and Drug Administration. FDA announces enhanced warnings for immediate-release opioid pain medications related to risks of misuse, abuse, addiction, overdose and death [press release]. March 22, 2016. Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491739.htm [Accessed July 13, 2016]
- Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158:1–9.
- Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.